{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:11:06Z","timestamp":1761894666307},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.ejca.2007.12.008","type":"journal-article","created":{"date-parts":[[2008,1,16]],"date-time":"2008-01-16T17:14:41Z","timestamp":1200503681000},"page":"366-373","source":"Crossref","is-referenced-by-count":20,"title":["Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice \u2013 Report of a European workshop"],"prefix":"10.1016","volume":"44","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"d\u2019Amore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Brammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 G\u00f3mez","family":"Codina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Illidge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Linkesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achiel","family":"Van Hoof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2007.12.008_bib1","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib2","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib3","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","article-title":"Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma","volume":"22","author":"Zinzani","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib4","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib6","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2007.12.008_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/cncr.22066","article-title":"Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma","volume":"107","author":"Weigert","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2007.12.008_bib9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/annonc\/mdi148","article-title":"Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma","volume":"16","author":"Hagenbeek","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/10428190600572582","article-title":"Yttrium 90 ibritumomab tiuxetan in lymphoma","volume":"47","author":"Cheung","year":"2006","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.ejca.2007.12.008_bib11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.beha.2006.05.002","article-title":"Radioimmunotherapy for B-cell non-Hodgkin lymphoma","volume":"19","author":"Witzig","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.ejca.2007.12.008_bib12","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell NHL treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2007.12.008_bib13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2767.2767","volume":"108","author":"Ogura","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib14","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin\u2019s lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib15","article-title":"Yttrium 90 ibritumomab tiuxetan (Zevalin\u00ae) is safe and effective in older patients with relapsed or refractory NHL","volume":"23","author":"Schilder","year":"2005","journal-title":"Proc ASCO"},{"key":"10.1016\/j.ejca.2007.12.008_bib16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-Hodgkin\u2019s lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib17","article-title":"Analysis of the incidence of treatment-related myelodysplastic syndrome and acute myelogenous leukaemia in registration and compassionate-use trials of ibritumomab tiuxetan radioimmunotherapy (RIT)","volume":"180","author":"Czuczman","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/00006231-200512000-00001","article-title":"Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin\u2019s lymphoma: is there an increased risk?","volume":"26","author":"Otte","year":"2005","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ejca.2007.12.008_bib19","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","article-title":"Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab","volume":"105","author":"Bennett","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190500376076","article-title":"Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin\u2019s lymphoma","volume":"47","author":"Emmanouilides","year":"2006","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.ejca.2007.12.008_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/asheducation-2004.1.203","article-title":"Low-grade lymphoma","author":"Winter","year":"2004","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ejca.2007.12.008_bib22","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib23","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib24","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-006-0207-0","article-title":"Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma-role of radioimmunotherapy","volume":"86","author":"Dreyling","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2007.12.008_bib26","first-page":"1236","article-title":"Management of nodal indolent (non marginal-zone) non-Hodgkin\u2019s lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation","volume":"90","author":"Barosi","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2007.12.008_bib27","article-title":"Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma","volume":"90","author":"Sweetenham","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2007.12.008_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.6577","article-title":"Rituximab with short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trial","volume":"23","author":"Shipley","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.7589","article-title":"Imaging results after CHOP-rituximab followed by 90Y-ibritumomab tiuxetan and rituximab (R) in patients with previously untreated follicular lymphoma (FL)","volume":"24","author":"Demonaco","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.4789.4789","article-title":"Safety and efficacy of fludarabine plus mitoxantrone (FM) followed by Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) and maintenance rituximab in intermediate- to high-risk newly diagnosed and relapsed follicular non-Hodgkin\u2019s lymphoma (NHL)","volume":"106","author":"Gregory","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib31","article-title":"Ibritumomab tiuxetan (Zevalin\u00ae) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission: interim analysis for safety of a multicenter, phase III clinical trial","volume":"102","author":"Radford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2747.2747","article-title":"90Y-Zevalin\u00ae (90Y-ibritumomab tiuxetan) radioimmunotherapy (RIT)Consolidation of FCM Induction chemotherapy in mantle cell lymphoma (MCL) patients: Results from the PLRG upon completed enrollment","volume":"108","author":"Jurczak","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.7503","article-title":"Phase II study of rituximab+CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group study (E1499)","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.926.926","article-title":"Early safety and efficacy analysis of a phase II study of sequential R-CHOP and Yttrium-90 ibritumomab tiuxetan (Zevalin\u00ae) for elderly high risk patients with untreated DLBCL","volume":"106","author":"Hamlin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib35","article-title":"A phase II trial of CHOP chemotherapy followed by Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma (DLBCL) patients","volume":"106","author":"Zinzani","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib36","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1200\/JCO.2002.10.143","article-title":"Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin\u2019s lymphoma","volume":"20","author":"Ansell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3816\/CLM.2004.n.028","article-title":"Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin\u2019s lymphoma: a review of the literature","volume":"5","author":"Ansell","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.ejca.2007.12.008_bib38","article-title":"Ongoing results of a phase I trial of two sequential doses of Y-90 ibritumomab tiuxetan (Zevalin\u00ae)for patients with relapsed low-grade non-Hodgkin lymphoma (NHL)","volume":"16","author":"Wiseman","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.17528","article-title":"Safety and efficacy of retreating follicular non-Hodgkin\u2019s lymphoma (NHL) with 90Y-ibritumomab tiuxetan","volume":"24","author":"Shah","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib40","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin\u2019s lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib41","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib42","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib43","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.12.008_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2007-01-068056","article-title":"Efficacy and safety of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation","volume":"110","author":"Morschhauser","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2007.12.008_bib45","article-title":"Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL)","volume":"106","author":"Younes","year":"2005","journal-title":"Blood"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804907009938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804907009938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T21:45:14Z","timestamp":1588283114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804907009938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0959804907009938"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2007.12.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}